Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Tar

Journal Article · · J. Am. Chem. Soc.
DOI:https://doi.org/10.1021/jacs.1c08060· OSTI ID:1867454
; ; ; ; ; ; ; ; ; ; ; ; ; ; ;

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; National Institutes of Health (NIH); OTHER
OSTI ID:
1867454
Journal Information:
J. Am. Chem. Soc., Vol. 143, Issue (49)
Country of Publication:
United States
Language:
ENGLISH

References (39)

SARS-CoV-2 variants, spike mutations and immune escape journal June 2021
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets journal December 2020
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV journal February 2020
SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model journal February 2021
Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection journal July 2021
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model journal May 2021
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease journal June 2020
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L journal November 2020
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 journal December 2021
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 journal October 2021
Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics journal May 2020
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease journal April 2020
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication journal August 2020
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice journal August 2020
A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors** journal December 2020
MPI8 is Potent against SARS‐CoV‐2 by Inhibiting Dually and Selectively the SARS‐CoV‐2 Main Protease and the Host Cathepsin L** journal July 2021
Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19 journal February 2021
Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir journal June 2021
ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model journal May 2021
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses journal March 2021
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 journal October 2020
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors journal April 2021
Discovery, Synthesis, And Structure-Based Optimization of a Series of N -( tert -Butyl)-2-( N -arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease journal January 2013
Advances in covalent kinase inhibitors journal January 2020
Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors journal November 2015
Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity? journal July 2019
Cysteine-reactive probes and their use in chemical proteomics journal January 2018
Organic Azide Inhibitors of Cysteine Proteases journal September 2006
Solid-Phase Synthesis of Azidomethylene Inhibitors Targeting Cysteine Proteases journal April 2008
The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization journal January 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 journal August 2021
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor journal April 2020
TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells journal October 2010
Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells journal July 2020
Cell entry mechanisms of SARS-CoV-2 journal May 2020
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease journal April 2021
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease journal October 2020
3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism † journal April 2004
Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors journal December 2020

Similar Records

Related Subjects